|
|
The 3rd World Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Hilton Hotel, Prague, Czech Republic, May 13-16, 2010 |
|
| |
| Program table |
 |
|
|
08:30-10:00 |
|
|
Plenary Session 1
Chairpersons: S. Del Prato, I. Raz
OUTCOME STUDIES IN THE TREATMENT OF TYPE 2 DIABETES (T2D)
Diabetes and Cancer
S. Del Prato
Implications of the new regulatory guidelines: cardiovascular outcome studies as an integral part of the development process of novel anti diabetic drugs
B. Hirshberg
What can we learn from the new ACCORD sub analysis?
H. Ginsberg
Act Now
R.A. DeFronzo
|
|
|
|
|
|
|
10:30-12:30 |
|
|
Session 2
Chairperson: J.J. Holst GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS: A CLINICAL COMPARISON
Glycaemic control impact on body weight potential to reduce CV risk
GLP-1: G. Sesti
DPP-4: D. Dicker
Beta-cell protection
Animal studies: M. Donath
Human perspective: A.J. Garber
PANEL DISCUSSION
D. Dicker, M. Donath, A.J. Garber G. Sesti |
Session 3
Chairperson: G. Mancia, Y. Yodfat
OPTIMAL BLOOD PRESSURE CONTROL
The blood pressure legacy
Pro: L. Ruilope
Con: G. Parati
Blood pressure: The lower, the better
Pro: G. Mancia
Con: A. Zanchetti
PANEL DISCUSSION
G. Mancia, G. Parati, L. Ruilope, A. Zanchetti |
Session 4
Chairperson: E. Ravussin
OBESITY: CAUSE AND DIFFERENT APPROACHES
Should obesity be treated at any age?
R. Bonadonna
Physical exercise. How and how much?
P. De Feo
Effective diet for weight loss
I. Shay
Caloric restriction V's bariatric surgery
E. Ravussin
PANEL DISCUSSION
R. Bonadonna, P. De Feo, E. Ravussin, I. Shai |
|
|
|
|
|
|
13:30-14:15 |
|
|
Plenary Session 5
NORMALIZING A1C – EFFICACY AND SAFETY OF NEW NOVEL DRUGS
R.A. DeFronzo |
|
|
|
14:15-16:00 |
|
|
Session 6
Chairpersons: A. Ametov, J. Meigs
THERAPY IN THE EARLY STAGE
Pharmacologic prevention of T2DM
Pro: R.A. DeFronzo
Con: J. Tuomilehto
Metformin failed: What is next?
Incretins: S. Del Prato
Others: I. Raz
PANEL DISCUSSION
R.A. DeFronzo, S. Del Prato, , I. Raz, J. Tuomilehto |
Session 7
Chairperson: E. Grossman
HYPERTENSION TREATMENT
Are the benefits of RAS blockage beyond BP lowering in CV prevention?
Y. Yodfat
Diuretics treatment of hypertension
Pro: E. Grossman
Con: P. Verdecchia
PANEL DISCUSSION
E. Grossman, P. Verdecchia, Y. Yodfat |
Session 8
Chairpersons: R. Niecestro, M. Petkova
GLUCOSE VARIABILITY
Postprandial glucose and glucose variability: Should we care?
Pro: A. Ceriello
Con: E. Standl
Continuous glucose monitoring (closing the loop)
Expectations: M. Philip
Humbles: J.H. DeVries
PANEL DISCUSSION
A. Ceriello, J.H. DeVries, M. Philip, E. Standl |
|
|
|
|
|
|
16:30-18:30 |
|
|
Session 9
Chairpersons: R.C. Bonadonna,
S. Chernia,
T2D IN CHILDHOOD
Epidemiology and pathophysiology
S. Caprio
Metabolic syndrome in pediatrics
R. Weiss
The accelerator hypothesis and the double diabetes
P. Pozzilli
Treatment of T2D in youth: What's on the Horizon?
S. Arslanian
PANEL DISCUSSION
S. Arslanian, S. Caprio, P. Pozzilli, R. Weiss, S. Arslanian
|
Session 10
Chairperson: L.M. Ruilope
RAS AND COMPLICATIONS
eGFR or albuminuria
as predictor for renal and CV outcome
eGFR: M. Ravid
Albuminuria: D. de Zeeuw
RAS blockade for every diabetic
Pro: L. Ruilope
Con: A. Solini
PANEL DISCUSSION
D. de Zeeuw, M. Ravid, L. Ruilope, A. Solini |
Session 11
Chairperson: C.D.A. Stehouwer
VESSELS, ENDOTHELIUM AND METABOLIC DISEASES
Inflammation and innate immunity
J.M. Fernández-Real
The role of metalloproteinases: At the interface between metabolic and inflammatory disorders
M. Federici
Vascular disease in diabetes: The role of repatory mechanisms
A. Avogaro
Endothelial factors and diabetic nephropathy
L. Gnudi
PANEL DISCUSSION
A. Avogaro, M. Federici, J.M. Fernández-Real, L. Gnudi |
|
|
08:30-10:00 |
|
|
Session 12
Chairpersons: P. Home, H. Toplak
LIPIDS IN THE WRONG PLACE
Islet fat
E. Ravussin
Intramyocellular
R.A. DeFronzo
Visceral fat/ NASH
G. Perseghin
Myocardial/Perivascular/ Epicardical fat
P. Iozzo |
Session 13
Chairpersons: G. Jermendy H. Lebovitz
THERAPY IN COMPLEX PATIENTS WITH TYPE 2 DIABETES CURRENT LIMITATIONS & FUTURE TREATMENT OPTIONS
Renally impaired T2DM
E. Ritz
T2DM with vascular complications. What is the target? Which treatment?
P. Pozzilli
Multidrug treatment of T2DM, a challenge for compliance
S. Del Prato
PANEL DISCUSSION
S. Del Prato, P. Pozzilli, E. Ritz |
Session 14
Chairpersons: A. Keidar
BARIATRIC SURGERY FOR T2DM REVERSAL
The evidence
G. Schernthaner
The mechanism
M. Fried
The risk
A. Keidar
PANEL DISCUSSION
M. Fried, A. Keidar, G. Schernthaner
|
|
|
|
|
|
|
10:30-12:30 |
|
|
Session 15
Chairperson: B. Frier J. Skrha
HYPOGLYCEMIA AND CV RISKS
Hypoglycemia and CV risks
B. Frier
ACCORD, ADVANCE and VADT
G. Schernthaner
Hypoglycaemia and it's potential contribution to fatal cardiac arrhythmias in T1D and T2D
S. Heller
PANEL DISCUSSION
B. Frier, S. Heller, G. Schernthaner |
Session 16
Chairperson: R. Fagard
INSULIN THERAPY
Insulin therapy in type 2 diabetes
Not too soon: H. Lebovitz
Not too late: L. Meneghini
HbA1c targets should be individualized for all patients with DM
Pro: P. Home
Con: L. Leiter
PANEL DISCUSSION
H. Lebovitz
PANEL DISCUSSION
P. Home,H. Lebovitz, L. Leiter, L. Meneghini
|
Session 17
Chairperson: H. Rosolova, A. Zambon
PREVENTION OF CVD
Diabetic dyslipidemia
statin Vs. combination therapy
Pro: R. Bitzur
Con: A. Zambon
Risk assessment of universal treatment
J. Meigs
PANEL DISCUSSION
R. Bitzur, J. Meigs, A. Zambon |
|
|
|
|
|
|
13:30-14:15 |
|
|
POSTER GUIDED TOURS
Posters Area
|
|
Session 18
Oral Presentations |
|
|
|
14:00-16:00 |
|
|
Session 19
Chairpersons: E. Bonora, J. Davidson
SAFETY – OPEN QUESTIONS
Incretins
J. J. Holst
Sulfonylurea
J. Davidson
PPAR-agonists: Safety issues
P. Home
PANEL DISCUSSION
J. Davidson, P. Home
|
Session 20
Chairpersons: L. Meneghini, A. Rubinstein NOVEL DRUGS FOR DIABETES
Novel mechanisms for the treatment of T2DM
H. Katzeff
The role of bile acid in T2D treatment
Y. Handelsman
Anticoagulatation for every diabetic? Pro: E. Standl
Con: A. Nicolucci
PANEL DISCUSSION
Y. Handelsman, H. Katzeff, A. Nicolucci, E. Standl |
Session 21
Chairperson: P.M. Nilsson
SMOKING CESSATION - GET READY FOR SUCCESS!
Evolutionary perspectives on addiction leading to smoking, obesity and drug abuse
P.M. Nilsson
Nicotine dependence: Why, how and when?
K.O. Fagerström
Smoking. The global epidemic
R. Fagard
Smoking cessation strategies. The evidence. Non-pharmacological support and counseling
P. Tønnesen
PANEL DISCUSSION
R. Fagard, K.O. Fagerström, P.M. Nilsson, P. Tønnesen |
|
|
|
|
|
|
16:30-18:30 |
|
|
Session 22
Chairpersons: L.A. Leiter, M. Shestakova
HYPERGLYCEMIA AND CVD
Is hyperglycemia a CV risk factor?
Pro: M. Hanefeld
Con: A. Natali
Heart in diabetes
A macrovascular disease:
D. Tschöpe
A microvascular disease:
M. Laakso
PANEL DISCUSSION
M. Hanefeld, M. Laakso, A. Natali, D. Tschöpe |
Session 23
Chairpersons: N.M. Lalic, R.A. DeFronzo
PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF OBESITY
Benefits of calorie intake control
N. Stern
Comparative efficiency and safety
V. Hainer
Sibutramine on CV outcome
A. Scheen
PANEL DISCUSSION
V. Hainer, A. Scheen, N. Stern |
Session 24
Chairperson: J.P. Després
THE CARDIOMETABOLIC BENEFITS OF MODERATE WEIGHT LOSS
Obesity management: Beyond weight loss
R. Ross
Reducing visceral adiposity/ ectopic fat: A better therapeutic target than weight loss?
J.P. Després
Variation in body weight associated with hypoglycaemic medication: more than a side effect in type 2 diabetes
M. Theodorakis
Novel hypoglycemic agents inducing weight loss
J.J. Holst
PANEL DISCUSSION
J.P. Després, J.J. Holst, R. Ross, M. Theodorakis
|
|
|
08:30-10:00 |
|
|
Session 25
Chairperson: A. Natali
HYPERTENSION IN DIABETES
Vascular disease endothelial function and clinical implication and endothelium: Target for therapy
A. Natali
Microvascular dysfunction as a central factor linking obesity to diabetes and hypertension
C.D.A. Stehouwer
PANEL DISCUSSION
A. Natali, C.D.A. Stehouwer |
Session 26
Chairpersons: D. Micic, E. Standl
CARDIOVASCULAR RISK FACTORS
Should CRP be a target of therapy?
L.A. Leiter
A1C Debate
Pro: E. Bonora
Con: J. Tuomilehto
PANEL DISCUSSION
E. Bonora, L.A. Leiter, J. Tuomilehto |
|
|
|
|
|
|
10:30-12:30 |
|
|
Session 27
BEST ABSTRACTS AWARD
Chairperson: I. Raz
FUTURE THERAPY OF T2D
GK Activator: F. Matschinsky
SGLT2: E. Boutati
Long Acting GLP1: A.J. Garber |
|
|
|
|
|
WebStudio.co.il